The pharmacokinetics of vigabatrin in rat blood and cerebrospinal fluid  X. Tong, N. Ratnaraj, P.N. Patsalos  Seizure - European Journal of Epilepsy  Volume 16, Issue 1, Pages 43-49 (January 2007) DOI: 10.1016/j.seizure.2006.10.003 Copyright © 2006 British Epilepsy Association Terms and Conditions

Figure 1 Vigabatrin concentration vs. time profiles in serum after 250mg/kg (♦), 500mg/kg (■) and 1000mg/kg (▴) vigabatrin administration. Data are mean±S.E.M. of 6–7 animals. Seizure - European Journal of Epilepsy 2007 16, 43-49DOI: (10.1016/j.seizure.2006.10.003) Copyright © 2006 British Epilepsy Association Terms and Conditions

Figure 2 Vigabatrin free/total concentration ratio at different vigabatrin concentrations (13–1378μmol/l) over time. Seizure - European Journal of Epilepsy 2007 16, 43-49DOI: (10.1016/j.seizure.2006.10.003) Copyright © 2006 British Epilepsy Association Terms and Conditions

Figure 3 Vigabatrin concentration vs. time profiles in CSF after 250mg/kg (▴), 500mg/kg (♦) and 1000mg/kg (■) vigabatrin administration. Data are mean±S.E.M. of 6–7 animals. Seizure - European Journal of Epilepsy 2007 16, 43-49DOI: (10.1016/j.seizure.2006.10.003) Copyright © 2006 British Epilepsy Association Terms and Conditions

Figure 4 Relationship between vigabatrin concentrations in serum and CSF. Data are those from 500mg/kg vigabatrin administration. The equation for linear regression is y=0.0149+5.8625; r2=0.7106. Seizure - European Journal of Epilepsy 2007 16, 43-49DOI: (10.1016/j.seizure.2006.10.003) Copyright © 2006 British Epilepsy Association Terms and Conditions

Figure 5 CSF/serum vigabatrin concentration ratios vs. time after 250mg/kg (■), 500 (♦) and 1000 (▴) mg/kg vigabatrin administration. Data are mean±S.E.M. of 6–7 animals. Seizure - European Journal of Epilepsy 2007 16, 43-49DOI: (10.1016/j.seizure.2006.10.003) Copyright © 2006 British Epilepsy Association Terms and Conditions